Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human PD-1 Anticorps:
anti-Rat (Rattus) PD-1 Anticorps:
anti-Mouse (Murine) PD-1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal PD-1 Primary Antibody pour BR, CyTOF - ABIN5012979
Wan, Nie, Liu, Feng, He, Xu, Zhang, Dong, Zhang: Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. dans Journal of immunology (Baltimore, Md. : 1950) 2007
Show all 21 Pubmed References
Human Polyclonal PD-1 Primary Antibody pour ELISA (Detection), FACS - ABIN4899871
Sakthivel, Ramanujam, Wang, Pirskanen, Lefvert: Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. dans Journal of neuroimmunology 2008
Show all 11 Pubmed References
Human Monoclonal PD-1 Primary Antibody pour BR, FACS - ABIN2689142
Bennett, Luxenberg, Ling, Wang, Marquette, Lowe, Khan, Veldman, Jacobs, Valge-Archer, Collins, Carreno: Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. dans Journal of immunology (Baltimore, Md. : 1950) 2003
Show all 8 Pubmed References
Mouse (Murine) Monoclonal PD-1 Primary Antibody pour BR, FACS - ABIN2689141
Nishimura, Agata, Kawasaki, Sato, Imamura, Minato, Yagita, Nakano, Honjo: Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. dans International immunology 1997
Show all 7 Pubmed References
Human Monoclonal PD-1 Primary Antibody pour ICC, FACS - ABIN438813
Dorrell, Abraham, Lanxon-Cookson, Canaday, Streeter, Grompe: Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. dans Stem cell research 2009
Show all 3 Pubmed References
Human Monoclonal PD-1 Primary Antibody pour ELISA, WB - ABIN532977
Latchman, Wood, Chernova, Chaudhary, Borde, Chernova, Iwai, Long, Brown, Nunes, Greenfield, Bourque, Boussiotis, Carter, Carreno, Malenkovich, Nishimura, Okazaki, Honjo, Sharpe, Freeman: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. dans Nature immunology 2001
Show all 3 Pubmed References
Human Polyclonal PD-1 Primary Antibody pour IHC, ELISA - ABIN1002980
Holling, Schooten, van Den Elsen: Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. dans Human immunology 2004
Show all 4 Pubmed References
Human Polyclonal PD-1 Primary Antibody pour IHC, ELISA - ABIN1002981
Ishida, Agata, Shibahara, Honjo: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. dans The EMBO journal 1992
Show all 4 Pubmed References
Mouse (Murine) Polyclonal PD-1 Primary Antibody pour CyTOF, FACS - ABIN4899873
Kasagi, Kawano, Okazaki, Honjo, Morinobu, Hatachi, Shimatani, Tanaka, Minato, Kumagai: Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. dans Journal of immunology (Baltimore, Md. : 1950) 2010
Show all 3 Pubmed References
Human Monoclonal PD-1 Primary Antibody pour IHC (p) - ABIN2717730
Panda, Mehnert, Hirshfield, Riedlinger, Damare, Saunders, Kane, Sokol, Stein, Poplin, Rodriguez-Rodriguez, Silk, Aisner, Chan, Malhotra, Frankel, Kaufman, Ali, Ross, White, Bhanot, Ganesan: Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. dans Journal of the National Cancer Institute 2019
Show all 2 Pubmed References
PD-1 expression in the natural killer cells in the head and neck cancer patients.
These results indicate that PD-L1 and PD-1 were highly expressed in triple negative breast cancer
PD-1 expression on tumor-infiltrating lymphocytes was significantly less frequent in male than in female cancers (48.9 vs. 65.3%, p = 0.002). PD-L1 expression on tumor and immune cells did not differ between the two groups. In male breast cancer, PD-1 and tumor PD-L1 were associated with grade 3 tumors. In female breast cancer, PD-1 and PD-L1 were associated with comparably worse clinicopathological variables.
This study provides novel mechanistic insights into how PD-1 inhibition disrupts NK cell function.
This study indicates that PD-1 is a key surface molecule controlling cell proliferation and multipotential differentiation of MSC-DP.
PD-L1 exposure increased proliferation and activated MAPK. Imaging PDTXs revealed uptake of radio-immunoconjugates. PD-1 knockdown in vivo revealed 67% smaller volumes than controls. Finally, ICI treatment of both PDOs/PDTXs demonstrated cytotoxicity and anti-MEK1/2 combined with anti-PD-1 drugs produced highest cytotoxicity in PDOs/PDTXs
Follicular helper T cells promote the effector functions of CD8(+) T cells via the expression of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer.
Rs10204525 and rs2227982 of programmed cell death 1 were associated with hepatitis b infection and the combination of the 2 sites can better predict host susceptibility
this study shows increased expression of PD-1 on CD4+ T cells of patients with asthma
HBV infection has a marked impact on global and HBV-specific humoral immunity, yet HBsAg-specific B cells are amenable to a partial rescue by B cell-maturing cytokines and PD-1 blockade.
these findings lay the basis for investigation of PD-1-expressing CD8+ T cell targeting strategies in human chronic inflammatory diseases.
We show that PD-1 knockdown enhances immediate tumor killing but is limited by compensatory engagement of alternative co-inhibitory and senescence program upon repetitive stimulation.
Among 21 cases of poorly differentiated non-keratinizing squamous cell carcinoma of the thymus. 15 showed various degrees of membranous PD-L1 staining and PD-1 staining showed focal positivity in 12 cases among tumor infiltrating lymphocytes.
study validated prior findings5 that diffuse large B-cell lymphoma (DLBCL) patients have a higher level of sPD-L1 at diagnosis compared to matched healthy controls, and that elevated levels of sPD-L1 is an adverse prognostic factor for overall survival in newly diagnosed DLBCL patients treated with rituximab plus anthracycline-based therapy
FISH technique and qPCR data coupled with immunofluorescence revealed that genetic alterations of 9p24.1 robustly contributed to PD-L1 and PD-L2 upregulation. In addition, increased expression of PD-L1 instead of PD-L2 also predicted poor survival by multivariate analyses. Meanwhile, high infiltration of PD-1(+) immune cells also indicated dismal survival in hepatocellular carcinoma.
present data provide the first evidence that human decidual group 3 innate lymphoid cells express a functional PD-1
The present study also investigated whether the PD-1 inhibitor affected the PD-1 mRNA expression in T cells or CAR-T cells. No difference in the PD-1 mRNA expression was observed among different T-cell or CAR-T-cell groups at different time points.
identification of patient subgroups responding less well to anti-PD-1 immunotherapy with our algorithm will not avoid these agents, but might obtain better monitoring, and hence more quickly identify progressive disease
Therapeutic indications and predictive factors for immunotherapy with anti-PD-1 and anti-PD-L1 antibodies in non-small cell lung cancer (NSCLC) patients are very diverse. Expression of PD-L1 on tumor cells and tumor mutations burden are neither the only nor the perfect predictors for immunotherapy.
the combination of the oncolytic immunotherapy with anti-PD-1 antibody dramatically improves the therapeutic outcome compared to either anti-PD-1 alone or vvDD-IL15-Ralpha alone.
Our findings confirm that PD-1 plays a vital role in peripheral blood lymphopenia and apoptosis caused by acute Bovine viral diarrhea virus infection, and provide new insights into exploring the immunopathological mechanisms of BVDV or other members of the Flaviviridae family, and a potential therapeutic strategy to control BVDV infection.
These results suggest that the PD-1/PD-L1 pathway could be involved in immune exhaustion of bovine mycoplasma-specific T cells. In conclusion, our study opens up a new perspective in the therapeutic strategy for bovine mycoplasmosis by targeting the immunoinhibitory receptor pathways.
PD-1 and LAG-3 cooperatively mediate the functional exhaustion of CD4(+) and CD8(+) T cells and are associated with the development of B-cell lymphoma in BLV-infected cattle.
M. bovis infection increased the expression of the PD-1 receptor on total PBMCs and in gated CD4(+) and CD8(+) T-cell subpopulations.
these findings suggest that IL6 is a rational immunosuppressive target for overcoming the narrow therapeutic window of anti-PD-1/PD-L1 therapy.Significance: These findings advance our understanding of IL6-PD1/PD-L1 cross-talk in the tumor microenvironment and provide clues for targeted interventional therapy that may prove more effective against cancer
when CTLA-4 and PD-1 antibodies were combined with DCR-BCAT in MMTV-Wnt1 transgenic mice, a genetic model of spontaneous Wnt-driven tumors, complete regressions were achieved in the majority of treated subjects. These data support RNAi-mediated b-catenin inhibition as an effective strategy to increase response rates to cancer immunotherapy.
experiments demonstrate that combination therapy with i.t. delivery of TLR agonists and PD-1 blockade activates TAMs and induces tumor-specific adaptive immune responses, leading to suppression of primary tumor growth and prevention of metastasis in HNSCC models
Liver-resident natural killer (LrNK) cells-mediated inhibition of T cell function was dependent on the programmed cell death protein 1 (PD-1)-programmed cell death 1 ligand 1 (PD-L1) axis.
Anti-PD-1 and anti PDL-1 do not increase the formation of ADA, but anti-CTLA-4 and anti-OX-40 do increase the onset of ADA.
these are the first studies to assess and compare "off-target" host secretory effects of VEGF and PD-1 pathway inhibition that occur independent of tumor stage or tumor response to therapy.
Our data demonstrate that PD1-PDL1 interaction is important to protect the heart from damage caused by infiltrating leukocytes in chronic Trypanosoma cruzi Infection.
data indicate that FBXO38 regulates PD-1 expression and highlight an alternative method to block the PD-1 pathway
Activation of PD-1 relieves intestinal immune defense injury through IL-10/miR-155 pathway.
this study shows that PD-1 expression is upregulated on adapted T cells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state
this study show that endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
obesity results in increased immune aging, tumor progression and PD-1-mediated T cell dysfunction which is driven, at least in part, by leptin.
both s-DAB-IL-2(V6A) and s-DAB-IL-2 given before checkpoint inhibition with anti-programmed cell death-1 (anti-PD-1) antibodies inhibited tumor growth, while either drug given as monotherapy had less effect. s-DAB-IL-2(V6A) is a second-generation diphtheria-toxin-based fusion protein with promise as a cancer immunotherapeutic both alone and in conjunction with PD-1 blockade
The blockade of inhibitory receptor PD-1 stimulated the production of IFNG in chronic T cells, but failed to shift their metabolism towards aerobic glycolysis, as observed in effector T cells.
by operating in both costimulatory and bystander signaling mode, PD-1 suppresses follicular T cell recruitment but promotes Follicular T Helper Cell concentration in the Germinal Center territory and helps maintain the stringency of Germinal Center affinity selection.
Treating mice first with anti-IL-1beta Abs followed by anti-PD-1 Abs completely abrogated tumor progression.
this report has identified a mechanism by which sustained PD-1 signaling induces robust regulatory function in inducible regulatory T cells through post-translational regulation of the Foxp3 protein.
Co-inhibiting the expressions of PD-1 and CTLA-4 can effectively suppress the growth of H22 hepatoma and promote the apoptosis of tumor cells in mice.
the PD-1 level observed at weeks after radiation exposure is connected to T cell dysfunction
Data show that CTLA-4(+)PD-1(-) memory CD4(+) T cells, which share phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood, lymph nodes (LN), spleen, and gut, and contained replication-competent and infectious virus.
Compared to before immunosuppression, PD-1 expression increased at reactivation. Increased T cells before zoster is likely due to virus reactivation.
A PD-1(high) phenotype is associated with accelerated in vivo CD8 T cell turnover in SIV-infections, especially within the SIV-specific CD8 T cell pool.
High levels of PD-1 expression on CD4(+) T cells in lymph nodes of rhesus macaques can serve as a valuable marker to identify T follicular helper cells.
Data indicate that PD-1 expression is increased as a result of T cell activation during a primary immune response as well as during persistent immune activation in macaques.
PD-1 can serve as a sensitive indicator of persistent, low-level virus replication
This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases.
programmed cell death protein 1
, protein PD-1
, programmed cell death 1
, programmed death 1